Kimberly Huff
Psychiatric/Mental Health · New Castle, INNPI 1528799749
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Alkermes, Inc. at 40.8% of the total. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$630
- Otsuka America Pharmaceutical, Inc.$422
- Axsome Therapeutics, Inc.$354
- Corium, LLC$328
- Lundbeck LLC$228
- plus $1K from 17 others
What the payments were for
- Food & beverage$5,317100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 79 | $2,170 |
| AbbVie | 47 | $630 |
| Otsuka America Pharmaceutical, Inc. | 22 | $422 |
| Axsome Therapeutics, Inc. | 14 | $354 |
| Corium, LLC | 20 | $328 |
| Lundbeck LLC | 16 | $228 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $218 |
| Neurocrine Biosciences, Inc. | 10 | $206 |
| Ironshore Pharmaceuticals Inc. | 8 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $154 |
| Johnson & Johnson | 5 | $101 |
| Indivior Inc. | 3 | $64 |
| Tris Pharma Inc | 4 | $64 |
| GSK | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Novo Nordisk | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,850
- LYBALVI$1,722
- ARISTADA INITIO$228
- Auvelity$122
How this compares
$5,317 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 43 | $163,679 |
| IngrezzaValbenazine Tosylate | 13 | $98,631 |
| AuvelityDextromethorphan Hbr/Bupropion | 96 | $92,570 |
| VraylarCariprazine Hcl | 57 | $88,515 |
| LybalviOlanzapine/Samidorphan Malate | 51 | $83,528 |
| Abilify AsimtufiiAripiprazole | 14 | $81,176 |
| CaplytaLumateperone Tosylate | 31 | $51,776 |
| Jornay PmMethylphenidate Hcl | 34 | $23,938 |
| MounjaroTirzepatide | 22 | $22,871 |
| BelsomraSuvorexant | 27 | $13,681 |
| Ramelteon | 57 | $9,628 |
| Lurasidone Hcl | 20 | $7,018 |
| Clomipramine Hcl | 48 | $6,059 |
| Lisdexamfetamine Dimesylate | 18 | $3,905 |
| Buspirone Hcl | 96 | $2,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi | $2,170 | $247,20694 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $206 | $98,63113 claims |
| Axsome Therapeutics, Inc.Auvelity | $354 | $92,57096 claims |
| AbbVieVraylar | $630 | $88,51557 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii | $422 | $81,17614 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $218 | $51,77631 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $159 | $23,93834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in New Castle
- Barbara LoganNew Castle$6K
- Kristin ManningNew Castle$6K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.